Guardant Health (GH)
NASDAQ:GH
Want to see GH full AI Analyst Report?
Top Page
Guardant Health
(NASDAQ:GH)
Select Model
Select Model
Rating:56Neutral
Price Target:
$134.00
▲(48.30% Upside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by weak financial fundamentals—large ongoing losses, negative cash flow, and a leveraged/negative-equity balance sheet. This is partially offset by strong technical uptrend signals and a positive earnings call featuring raised revenue guidance and improving screening economics, though reinvestment-driven expense growth and continued cash burn keep risk elevated.
Positive Factors
Revenue growth and raised guidance
Sustained top-line acceleration and materially higher guidance reflect expanding test volumes across Oncology and Screening. Durable revenue expansion improves operating leverage potential and underpins reinvestment capacity, making growth-driven path to profitability more achievable over the next 2–3 years.
Negative Factors
High leverage and negative equity
Material leverage and negative equity constrain financial flexibility and increase refinancing and interest risks. Until operating profits accumulate, the balance sheet limits strategic optionality, raises liquidity sensitivity to shocks, and could increase cost of capital for longer‑term investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and raised guidance
Sustained top-line acceleration and materially higher guidance reflect expanding test volumes across Oncology and Screening. Durable revenue expansion improves operating leverage potential and underpins reinvestment capacity, making growth-driven path to profitability more achievable over the next 2–3 years.
Read all positive factors
Guardant Health Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyGuardant Health (GH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.25B
Dividend YieldN/A
Average Volume (3M)2.37M
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth39.56%
EPS Growth-0.63%
CountryUS
Employees1,999
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-3.39
Shares Outstanding132,599,930
10 Day Avg. Volume2,609,109
30 Day Avg. Volume2,366,648
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue16.56
Enterprise Value/Gross Profit25.51
Enterprise Value/Ebitda-45.74
Forecast
1Y Price Target
$140.94Price Target Upside55.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.93
Revenue Forecast (FY)$1.31B
Guardant Health Business Overview & Revenue Model
Company Description
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and ...
How the Company Makes Money
Guardant Health generates revenue primarily from selling oncology diagnostic tests and related services. Key revenue streams include: (1) Clinical testing revenue: fees paid for performing Guardant’s molecular tests on patient samples (notably liq...
Guardant Health Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call presented a strongly positive operational and commercial quarter: revenue growth was robust across Oncology, Biopharma & Data and Screening, Shield showed breakout traction with meaningful margin improvement, and product and data investments (InfinityAI, NovaSeq X transition, expanded FDA approvals and partnerships) support multi-year upside. Key near-term challenges include elevated operating expenses to fund growth, ongoing adjusted losses and free cash flow burn, and dependencies on reimbursement and third-party regulatory outcomes (MolDx reviews, drug approvals) that introduce timing and upside uncertainty. Overall, positives (accelerating revenue, volume, margin improvement, data/AI progress, and strengthened partnerships) materially outweigh the risks, though execution and reimbursement milestones remain important to sustain momentum.Positive Updates
Strong Top-Line Revenue Growth and Raised Guidance
Q1 revenue of $302 million, up 48% year-over-year; company surpassed $1 billion trailing 12-month revenue. Raised full-year 2026 revenue guidance to $1.30B–$1.32B (32%–34% growth).
Negative Updates
Increased Operating Expense Base
Non-GAAP operating expenses rose 34% YoY to $268 million, driven primarily by sales & marketing investments (S&M rose to $154M from $94M) to scale screening and commercial activities. Full-year non-GAAP operating expense guidance increased to $1.05B–$1.07B (+16%–18% YoY) as incremental screening gross profit will be reinvested.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Revenue Growth and Raised Guidance
Q1 revenue of $302 million, up 48% year-over-year; company surpassed $1 billion trailing 12-month revenue. Raised full-year 2026 revenue guidance to $1.30B–$1.32B (32%–34% growth).
Read all positive updates
Company Guidance
Guardant raised 2026 guidance to $1.30–$1.32 billion in revenue (up 32–34% YoY), with Oncology revenue growth now expected at 28–29% (volume growth >35%), Biopharma & Data to grow in the low double‑digit range, and Screening revenue now forecast at $186–$198 million driven by ~230,000–245,000 Shield tests (guidance excludes potential upside from ACS guideline inclusion); full‑year non‑GAAP gross margin is guided to 64–65%, non‑GAAP operating expenses to $1.05–$1.07 billion (up 16–18% vs. 2025) as incremental Shield gross profit is reinvested, and full‑year free cash‑flow burn is expected to be $185–$195 million (improving YoY) with the business ex‑Screening projected to be free‑cash‑flow positive and company‑wide cash‑flow breakeven targeted by end of 2027; management also noted upside is possible from FDA approval of Guardant360 Liquid or the launch of Reveal Ultra and expects Shield cost per test to decline toward ~$200 at scale (targeted in 2027).Guardant Health Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
18
Very Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 982.02M | 739.02M | 563.95M | 449.54M | 373.65M |
| Gross Profit | 701.01M | 633.01M | 449.22M | 336.90M | 293.21M | 250.74M |
| EBITDA | -390.98M | -373.91M | -390.12M | -433.31M | -614.91M | -359.62M |
| Net Income | -433.19M | -416.28M | -436.37M | -479.45M | -654.59M | -405.67M |
Balance Sheet | ||||||
| Total Assets | 1.92B | 2.01B | 1.49B | 1.79B | 1.61B | 2.20B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 1.20B | 839.98M | 1.17B | 1.01B | 932.75M |
| Total Debt | 1.68B | 1.68B | 1.34B | 1.35B | 1.37B | 1.37B |
| Total Liabilities | 2.10B | 2.11B | 1.63B | 1.63B | 1.55B | 1.56B |
| Stockholders Equity | -181.07M | -99.31M | -139.65M | 158.68M | 60.18M | 645.00M |
Cash Flow | ||||||
| Free Cash Flow | -224.83M | -233.07M | -274.94M | -345.46M | -386.92M | -284.05M |
| Operating Cash Flow | -175.41M | -184.76M | -239.86M | -324.98M | -309.46M | -209.02M |
| Investing Cash Flow | -230.65M | -627.20M | -261.31M | 840.25M | 149.82M | -63.16M |
| Financing Cash Flow | 704.12M | 671.13M | -996.00K | 477.38M | -189.09M | -66.82M |
Guardant Health Technical Analysis
Positive
90.36
Price Trends
100.36
Positive
99.96
Positive
91.60
Positive
Market Momentum
9.23
Negative
67.03
Neutral
52.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GH, the sentiment is Positive. The current price of 90.36 is below the 20-day moving average (MA) of 117.40, below the 50-day MA of 100.36, and below the 200-day MA of 91.60, indicating a bullish trend. The MACD of 9.23 indicates Negative momentum. The RSI at 67.03 is Neutral, neither overbought nor oversold. The STOCH value of 52.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GH.
Guardant Health Risk Analysis
Guardant Health disclosed 70 risk factors in its most recent earnings report. Guardant Health reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Guardant Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $7.78B | 19.43 | 11.28% | 3.31% | 4.79% | 333.61% | |
63 Neutral | $11.62B | 48.35 | 3.28% | 0.29% | 4.79% | -16.36% | |
63 Neutral | $31.91B | -139.32 | -15.13% | ― | 36.59% | -11.94% | |
56 Neutral | $17.25B | -39.43 | 184.27% | ― | 39.56% | -0.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $4.42B | -305.04 | -1.36% | ― | 14.72% | 59.37% |
* Healthcare Sector Average
GH
Guardant Health
130.12
80.03
159.77%
RVTY
Revvity
104.13
8.16
8.50%
QGEN
Qiagen
37.75
-8.31
-18.04%
RDNT
Radnet
56.18
-3.11
-5.25%
NTRA
Natera
222.82
57.60
34.86%
Guardant Health Corporate Events
Business Operations and StrategyExecutive/Board Changes
Guardant Health Announces Resignation of Chief Medical Officer
Negative
Apr 27, 2026
On April 27, 2026, Guardant Health, Inc. announced that its Chief Medical Officer, Craig Eagle, M.D., has resigned, with his departure to take effect on May 8, 2026. The exit of the company’s top medical executive marks a notable leadership ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.